LCAR-B38M CAR-T cell therapy promising at 4-year follow-up for treatment of refractory multiple myeloma | 2 Minute Medicine
2 Minute Medicine ,
1. At a 4-year follow-up for relapsed or refractory multiple myeloma (RRMM) patients treated with LCAR-B38M CAR-T cell therapy…